CEO Dennis Calvert Gives a Personal Interview on the Symposium’s Positive Outcome and BioLargo’s Current Accomplishments

Westminster, CA (Uptick Newswire – August 28, 2017) – Mr. Dennis Calvert, CEO of BioLargo, Inc. (OTCQB:BLGO), interviews on the Uptick Network with host Everett Jolly. Mr. Calvert gives a personal interview on BioLargo’s third annual technical symposium and the science behind its AOS (Advanced Oxidation System). Mr. Calvert elaborates on the Alpha unit’s performance on client-provided water from poultry, dairy, and municipal wastewater, and explains the data outcome that the AOS is proven to solve specific problems and what this could mean for the marketplace. With presenting four other designs at the symposium, Mr. Calvert clarifies how the designs work and that some were tested to show the effectiveness and the multiple purposes that these devices accomplish.

Mr. Calvert also reviewed the status of the company’s medical technologies, commenting on subsidiary Clyra Medical’s efforts and accomplishments, including the status of FDA filings and what this means for the company and product. For industrial odor, Mr. Calvert reviews the hardships of the introduction of CupriDyne Clean to the markets and explains how the growth of the product is being accepted in the market now and what this means for BioLargo’s future.

In closing Mr. Calvert states, “The point for investors is to understand that this is a highly evolving company, with a bright future, a great opportunity and we are narrowing and focusing to execute on high value proposition. The opportunity are so expansive that if you look at us today and you wait 6 months the company is literally morphing every 6 months into this machine that has this momentum, the talent, the infrastructure, and all the tools to execute. So we’re very excited and thank you for all the support.”

Listen to the full interview by clicking here or the following link: https://stockdaymedia.com/featured-interview-ceo-dennis-calvert-of-biolargo-inc-otcqbblgo-update

About BioLargo, Inc. 
BioLargo, Inc. (BLGO)  is a sustainable science and technology company that makes life better by delivering award-winning products for clean water, clean air and advanced wound care. More information can be found about the company and its subsidiaries at www.BioLargo.com. Its subsidiary BioLargo Water, Inc. (www.BioLargoWater.com) showcases its emerging technology, the Advanced Oxidation System “AOS”, an award-winning product, having been awarded more than 35 research grants and counting, specifically designed to eliminate common, troublesome, and dangerous (toxic) contaminants in water in a fraction of the time and cost of current technologies. BioLargo’s subsidiary Odor-No-More Inc., features sustainable odor elimination products including its CupriDyne Clean (www.CupriDyne.com) Industrial Odor Eliminator, a product currently serving the leading solid waste handling and wastewater treatment companies as well as any industry that must contend with malodors, VOC’s or similar air quality related problems. Its personal care products are finding adoption through white labeling or early market entry in the pet, equine, military supply and consumer markets, and include the Nature’s Best Solution® and Deodorall® brands (www.OdorNoMore.com). BioLargo’s subsidiary Clyra Medical Technologies, Inc. (www.ClyraMedical.com) focuses on advanced wound care management featuring effective and gentle solutions for chronic infected wounds and other uses to promote infection control. BioLargo also owns a 50% interest in the Isan System, a fully automated iodine dosing system being commercialized under a license to Clarion Water, Inc.

 

Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo’s current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo’s Annual Report on Form 10-K.

Contact:
Company Contact
Dennis Calvert
President and CEO
BioLargo, Inc.
949-643-9540 x2

Source: Uptick Newswire

Leave a Reply